x

Posted 06 April, 2023

Sio Gene Therapies Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:SIOX in a 8-K filed on 06 April, 2023.


  Effective upon the approval by the Company's stockholders of the liquidation and dissolution of the Company (the "Dissolution") pursuant to the Plan of Complete Liquidation and Dissolution (the "Plan of Dissolution"), which authorizes the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution, each of the directors of the Company other than David Nassif, the Company's Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, and General Counsel, resigned in connection with the Company's dissolution.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Sio Gene Therapies Inc.
Health Care/Life Sciences • Biotechnology
Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY.
Market Cap
N/A
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On April 5, 2023, Sio Gene Therapies Inc. (the "Company") held a special meeting of its stockholders (the "Special Meeting") to vote on the three proposals described in detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on February 21, 2023 and mailed to the Company's stockholders on or about such date (the "Proxy Statement"). Effective upon the approval by the Company's stockholders of the liquidation and dissolution of the Company (the "Dissolution") pursuant to the Plan of Complete Liquidation and Dissolution (the "Plan of Dissolution"), which authorizes the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution, each of the directors of the Company other than David Nassif, the Company's Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, and General Counsel, resigned in connection with the Company's dissolution. No disagreement exists between the Company and any such director on any matter relating to the Company's operations, policies or practices.